In the interview, Mazumdar-Shaw outlined her succession plan as she prepares the four-decade-old group for its next phase of ...

Biocon founder and chairperson Kiran Mazumdar-Shaw said markets had read too much into the reports of her succession plan and ...

By Rishika Sadam May 5 (Reuters) - Biocon founder and chairperson Kiran Mazumdar-Shaw plans a gradual leadership transition ...

In a post on social network platform X, formerly Twitter, Shaw detailed out that Claire will eventually step into the role ...

Biocon founder Kiran Mazumdar-Shaw names niece Claire Mazumdar as successor under a phased five-year transition plan.

Biocon founder Kiran Mazumdar-Shaw outlines a five-year transition plan, naming niece Claire Mazumdar as successor to lead ...

Biocon’s fair value estimate has been trimmed slightly from ₹420.74 to about ₹416.53, signalling a modest reset in how analysts are sizing up the stock today. That shift lines up with a broader, more ...

Claire, 37, at present serves as founder and chief executive of Bicara Therapeutics, a biotech company incubated by Biocon ...

Claire Mazumdar, 37, is a biotech specialist and the founding CEO of Bicara Therapeutics, a clinical-stage oncology firm ...

Shaw, founder and chairperson of Biocon, has found her successor within the family. She outlined a gradual succession plan, ...

Kiran Mazumdar-Shaw's niece Claire Mazumdar is the CEO of Bicara Therapeutics.